John P. Kelley MBA — Director at Acorda Therapeutics

Mr. John P. Kelley, MBA Co-founded Phyxius Pharma, Inc. in 2011 and serves as its Chief Executive Officer. Mr. Kelley has been a Consultant of Tenax Therapeutics, Inc. since April 3, 2017. Mr. Kelley served as the Chief Executive Officer of Tenax Therapeutics, Inc. from November 14, 2013 to April 3, 2017. He served as the President and Chief Operating Officer of The Medicines Co. from December 2, 2004 to October 1, 2009. Mr. Kelley started his tenure at the Medicines Company from Aventis Pharmaceuticals, Inc., with close to 37 years of experience in the pharmaceutical industry. He served as Senior Vice President of Global Marketing & Medical at Aventis Pharmaceuticals Inc., and accountable for worldwide brand management of all of The Medicines Co.'s major franchise areas, including Cardiology/Thrombosis, Metabolism/Diabetes, Anti-Infectives and Arthritis/Osteoporosis. He served at Aventis Pharmaceuticals, Inc. as Senior Vice President of Strategic Risk Officer and Vice President, Head of Strategic Development, leading the strategic planning process of the pharmaceutical division of Aventis as well as merger and acquisition activity. He served as the head of all U.S. commercial activities for Hoechst Marion Roussel, Inc. Mr. Kelley's experience includes work on several successful cardiovascular and critical care brands including, Angiomax, Lovenox, Cardizem and Altace as well as other large non cardiovascular brands including Lantus, Copaxone, Allegra and Actonel. Mr. Kelley ran all aspects of product marketing for Marion Merrell Dow, Inc. During Mr. Kelley's tenure at Aventis Pharma and predecessor companies, he was involved with the launch of 20 products, including Cardizem(R) CD (diltiazem HCl), Allegra(R) (fexofenadine), and Actonel(R) (risedronate sodium). He started his career at Marion Laboratories Inc. as a sales representative, moving into positions of increasing responsibility in marketing, product management and strategic marketing with Marion Merrill Dow and eventually becoming Vice President and Commercial Director, U.S. at Hoechst Marion Roussel. Following the 2000 merger to create Aventis, Mr. Kelley became head of strategic development. He served as Vice President of Marketing of Hoechst Marion Roussel from 1995 to 1998. He has been a Director of Acorda Therapeutics, Inc. since December 2008. He served as a Director of Tenax Therapeutics, Inc. from December 19, 2013 to April 3, 2017. He served as a Director of The Medicines Co. since February 2005. Mr. Kelley received a B.A. and B.S. degree in Biology from Wilkes University and an MBA degree from Rockhurst University.